EUVIMEDEUVIMED entdecken
Crossref

Type 2 diabetes affects arsenic metabolism via transporters in arsenic trioxide treated acute promyelocytic leukemia patients

Mengliang Wu, Chunrong Pang, Shengwen Lu, Thomas H Hostetter, Xin Hai

Environmental Toxicology and Pharmacology · 2023

DOI: 10.1016/j.etap.2023.104142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Environmental Toxicology and Pharmacology, 2023. Verfasst von Mengliang Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, First Affiliated Hospital of Harbin Medical University, 23 YouZheng Str, Nangang District, Harbin, China; Heilongjiang Univer…. Hauptthemen laut MEDLINE: Arsenic, Leukemia, Promyelocytic, Acute, Antineoplastic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our study aimed to explore whether type 2 diabetes (T2DM) can affect arsenic metabolism in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide. We found that compared with non-diabetic APL patients, the concentrations of arsenic metabolites in APL patients with T2DM increased significantly and positively correlated with blood glucose (P < 0.05). Meanwhile, APL patients with T2DM were more prone to liver injury and QTc interval prolongation due to altered arsenic methylation capacity. Then we cultured HEK293T cells at different glucose concentrations, and the results showed that the cells with high glucose had higher concentrations of arsenic metabolites compared to other cells. Meanwhile, the high glucose significantly increased the mRNA and protein expression levels of the arsenic uptake transporter AQP7 in HEK293T cells. Overall, our study demonstrated that T2DM can lead to elevated concentrations of arsenic metabolites in APL patients by increasing AQP7 expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ArsenicLeukemia, Promyelocytic, AcuteAntineoplastic AgentsDiabetes Mellitus, Type 2ArsenicalsHumansArsenic TrioxideHEK293 CellsOxidesGlucose

Stichwörter der Autor:innen

Acute promyelocytic leukemiaArsenic metabolismArsenic trioxideTransporterType 2 diabetes mellitus

Substanzen

Arsenic TrioxideArsenicAntineoplastic AgentsArsenicalsOxidesGlucose

Autor:innen und Institutionen

  • Department of Pharmacy, First Affiliated Hospital of Harbin Medical University, 23 YouZheng Str, Nangang District, Harbin, China; Heilongjiang University of Chinese Medicine, 24 Heping Road, Xiangfang District, Harbin 1…
  • Department of Pharmacy, First Affiliated Hospital of Harbin Medical University, 23 YouZheng Str, Nangang District, Harbin, China.
  • Heilongjiang University of Chinese Medicine, 24 Heping Road, Xiangfang District, Harbin 150040, China.
  • School of Medicine, University of North Carolina, Chapel Hill, NC, United States of America.
  • Department of Pharmacy, First Affiliated Hospital of Harbin Medical University, 23 YouZheng Str, Nangang District, Harbin, China. Electronic address: hai_xin@163.com.

Zitieren

APA

Wu, M., Pang, C., Lu, S., Hostetter, T. H., & Hai, X. (2023). Type 2 diabetes affects arsenic metabolism via transporters in arsenic trioxide treated acute promyelocytic leukemia patients. Environmental Toxicology and Pharmacology. https://doi.org/10.1016/j.etap.2023.104142

Vancouver

Wu M, Pang C, Lu S, Hostetter TH, Hai X. Type 2 diabetes affects arsenic metabolism via transporters in arsenic trioxide treated acute promyelocytic leukemia patients. Environmental Toxicology and Pharmacology. 2023. doi:10.1016/j.etap.2023.104142

BibTeX
@article{Wu2023,
  author = {Wu, Mengliang and Pang, Chunrong and Lu, Shengwen and Hostetter, Thomas H and Hai, Xin},
  title = {Type 2 diabetes affects arsenic metabolism via transporters in arsenic trioxide treated acute promyelocytic leukemia patients},
  journal = {Environmental Toxicology and Pharmacology},
  year = {2023},
  doi = {10.1016/j.etap.2023.104142}
}
Kostenlos starten →